Bridging the gap in your Phase I clinical studies. 

Japan’s pharmaceutical market is the second largest in the world. Japan relies on the import of pharmaceutical goods to meet the needs of the country’s population. To capitalise upon these opportunities, drug developers must comply with the strict Pharmaceuticals and Medical Devices Agency (PMDA) regulations. 

Richmond Pharmacology’s expertise can help you bridge the gap in your next Phase I clinical study.

x

Learn about the bridging studies conducted at Richmond Pharmacology

A single centre study for Chiesi Pharmaceuticals. 16 Japanese and 16 Caucasian volunteers participated in cross over, bridging study for Chronic obstructive pulmonary disease. Read about our approach and the controls we introduced to reduce variability. Learn more here.

A cognitive function profile of a second generation antihistamine. The effect of rupatadine on cognitive functioning was evaluated by means of computerized cognitive tests: rapid visual information processing (RVP), reaction time (RT), spatial working memory (SWM) and visual analogue scales (VAS) with 27 Japanese volunteers. Learn more here.

Fast track your global marketing approvals

Our expertise can help you accelerate your drug development timelines globally

Get in touch today

Why choose Richmond Pharmacology for your Bridging Study

TAP OR CLICK A BLOCK BELOW TO LEARN MORE

Expertise in PMDA criteria

We have conducted more than 100 ethnic bridging studies enabling us to build a trusted relationship with the PMDA.

Read more +

13,000 active 1st generation Japanese subjects

Our recruitment database is the largest in Europe with more than 13,000 active 1st generation Japanese subjects. 

Read more +

Short- and long-term residency periods

We can accommodate studies with short-term and long-term residency periods.

Read more +

Richmond Pharmacology's ethnic bridging studies will reduce the PMDA approval timeline and accelerate your time to market.

Latest news

Richmond Pharmacology appoints Sandra Johnson as Director of Commercial Project Management

September 19, 2022
We are delighted to announce that Sandra Johnson will join Richmond Pharmacology as its new Director for Commercial Project Management
Read more

How telemonitoring can revolutionise the way we treat patients – Tom York

November 17, 2022
Richmond Pharmacology always searches for the most innovative processes to improve clinical trials and the patients’ experiences and treatments.
Read more

Events

JPW2022 (Japan Basic and Clinical Pharmacology Week 2022)

30 November – 3 December 2022
This event will be the 96th Annual Meeting of the Japanese Pharmacological Society and the 43rd Annual Meeting of the Japanese Society of Clinical Pharmacology. 
View event